| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0197-4580(97)00057-2 |
| P2860 | cites work | Neuropathological stageing of Alzheimer-related changes | Q27860862 |
| The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease | Q29614948 | ||
| Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop | Q34736093 | ||
| Diagnosis of Alzheimer's disease | Q69871134 | ||
| P433 | issue | 4 | |
| P921 | main subject | diagnosis | Q16644043 |
| P304 | page(s) | S1-S2 | |
| P577 | publication date | 1997-07-01 | |
| P1433 | published in | Neurobiology of Aging | Q7002141 |
| P1476 | title | Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease | |
| P478 | volume | 18 |
| Q24628115 | "Hairy baskets" associated with degenerative Purkinje cell changes in essential tremor |
| Q34464926 | 24-hour rhythms of DNA methylation and their relation with rhythms of RNA expression in the human dorsolateral prefrontal cortex |
| Q35442887 | A comparison of Aβ amyloid pathology staging systems and correlation with clinical diagnosis |
| Q48326013 | A grading system of Alzheimer disease lesions in neocortical areas |
| Q34005558 | A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder |
| Q34343403 | A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease |
| Q36190490 | A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules |
| Q28539868 | A systematic review of biomarkers for disease progression in Alzheimer's disease |
| Q34077399 | A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events |
| Q35006687 | Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies |
| Q28756638 | Accuracy of dementia diagnosis: a direct comparison between radiologists and a computerized method |
| Q34262758 | Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. |
| Q31968497 | Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures |
| Q35855302 | Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson's Disease Patients |
| Q36554589 | Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease |
| Q28200985 | Altered subcellular distribution of transcriptional regulators in response to Abeta peptide and during Alzheimer's disease |
| Q37180666 | Alzheimer disease pathology as a host response |
| Q40107949 | Alzheimer's disease or Alzheimer's syndrome?: a longitudinal computed tomography neuroradiological follow-up study of 56 cases diagnosed clinically as Alzheimer's disease |
| Q37405016 | Amyloid Plaques in Retina for Diagnosis in Alzheimer's Patients: a Meta-Analysis. |
| Q48876259 | Amyloid plaques dissociate pentameric to monomeric C-reactive protein: a novel pathomechanism driving cortical inflammation in Alzheimer's disease? |
| Q48300537 | Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease |
| Q48266946 | Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease |
| Q73114142 | Apolipoprotein E and the neuropathology of Alzheimer's disease |
| Q37100964 | Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia |
| Q33532794 | Apolipoprotein-E forms dimers in human frontal cortex and hippocampus |
| Q48493664 | Argyrophilic grain disease in demented subjects presenting initially with amnestic mild cognitive impairment |
| Q36593963 | Assessing Fluctuating Cognition in Dementia Diagnosis: Interrater Reliability of the Clinician Assessment of Fluctuation. |
| Q42132599 | Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins. |
| Q28488690 | Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy |
| Q35212618 | Biomarkers of Alzheimer's disease and mild cognitive impairment: are we there yet? |
| Q34034151 | Brain aging in the oldest-old |
| Q30378181 | Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. |
| Q36990425 | CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology |
| Q48187646 | Circle of Willis Atherosclerosis Is a Risk Factor for Sporadic Alzheimer’s Disease |
| Q50981551 | Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir. |
| Q35776895 | Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p |
| Q42527156 | Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease |
| Q36632771 | Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology |
| Q33456273 | Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers |
| Q53265435 | Combining correlated diagnostic tests: application to neuropathologic diagnosis of Alzheimer's disease. |
| Q35240139 | Comparison of Vascular Perturbations in an Aβ-Injected Animal Model and in AD Brain |
| Q48662441 | Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease |
| Q48865165 | Cortical synapse loss in progressive supranuclear palsy. |
| Q48104013 | Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain |
| Q53232722 | Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. |
| Q53233486 | Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. |
| Q57724897 | Dementia in the oldest old |
| Q37219298 | Dementia of the Alzheimer type |
| Q34089759 | Diagnostic Tests for Alzheimer's Disease: Rationale, Methodology, and Challenges |
| Q48493675 | Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment |
| Q36867708 | Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease |
| Q36744396 | Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration |
| Q34472845 | Distribution and Expression of Picalm in Alzheimer Disease |
| Q37739209 | Diurnal and seasonal molecular rhythms in human neocortex and their relation to Alzheimer's disease |
| Q24633872 | Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons |
| Q35063586 | Down-regulation of mortalin exacerbates Aβ-mediated mitochondrial fragmentation and dysfunction |
| Q46538558 | Early neuropsychological discriminants for Lewy body disease: an autopsy series |
| Q46157823 | Early-onset Alzheimer's disease is associated with greater pathologic burden |
| Q44444462 | Early‐onset Alzheimer's disease with presenilin‐1 M139V mutation: clinical, neuropsychological and neuropathological study |
| Q43838097 | Ectopic white matter neurons, a developmental abnormality that may be caused by the PSEN1 S169L mutation in a case of familial AD with myoclonus and seizures |
| Q41273331 | Effect of APOE Genotype on Synaptic Proteins in Earlier Adult Life |
| Q34512386 | Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression |
| Q48497682 | Elevated zinc transporter-6 in mild cognitive impairment, Alzheimer disease, and pick disease |
| Q33634163 | Enrichment of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by mass spectrometry |
| Q28471701 | Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study |
| Q36488586 | Essential tremor followed by progressive supranuclear palsy: postmortem reports of 11 patients |
| Q37656915 | Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center |
| Q27303745 | Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation |
| Q48939073 | Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in beta-amyloid load |
| Q35083342 | Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology |
| Q36558318 | F2-dihomo-isoprostanes arise from free radical attack on adrenic acid |
| Q60617957 | FDG-PET in Dementia |
| Q37572454 | Factors determining disease duration in Alzheimer's disease: a postmortem study of 103 cases using the Kaplan-Meier estimator and Cox regression |
| Q35977445 | Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases |
| Q49077318 | Feature extraction and strategy of analyzing structural neuroimaging in dementia |
| Q34333511 | Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study |
| Q46788465 | Focally elevated creatine detected in amyloid precursor protein (APP) transgenic mice and Alzheimer disease brain tissue |
| Q48587961 | Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease |
| Q48002156 | Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition |
| Q37139063 | Genetic aspects of Alzheimer disease |
| Q35889850 | Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors |
| Q34604101 | Genetics of Alzheimer disease |
| Q31919685 | High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner |
| Q35997631 | Hippocampal drebrin loss in mild cognitive impairment |
| Q48307556 | Hippocampal sclerosis in a case of Alzheimer's disease‐like dementia with late onset intractable epilepsy |
| Q38359613 | Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb |
| Q48698441 | Increased cAMP immunostaining in cerebral vessels in Alzheimer's disease |
| Q33605481 | Increased matrix metalloproteinase 9 activity in mild cognitive impairment |
| Q47292504 | Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease |
| Q34997879 | Inherited dementias |
| Q28751409 | Intermediate phenotypes identify divergent pathways to Alzheimer's disease |
| Q64054840 | Interpretable classification of Alzheimer’s disease pathologies with a convolutional neural network pipeline |
| Q39599916 | Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. |
| Q43867233 | Involvement of microtubule integrity in memory impairment caused by colchicine |
| Q24298553 | Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease |
| Q53235439 | Laminar specific loss of isocortical presenilin 1 immunoreactivity in Alzheimer's disease. Correlations with the amyloid load and the density of tau-positive neurofibrillary tangles. |
| Q36635968 | Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples |
| Q34327102 | Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? |
| Q42515808 | Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease |
| Q35064701 | Loss of motor function in preclinical Alzheimer's disease |
| Q40766812 | MRI description of cerebral atrophy in mouse lemur primates |
| Q44185145 | Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. |
| Q37669025 | MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma |
| Q37596385 | MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects |
| Q30844900 | Neuroimaging in Alzheimer disease: an evidence-based review |
| Q53265445 | Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. |
| Q34088144 | Neuropathologic substrates of ischemic vascular dementia |
| Q44823227 | Neuropathological and clinical phenotype of an Italian Alzheimer family with M239V mutation of presenilin 2 gene. |
| Q36817040 | Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? |
| Q51727637 | Neuropathology of mild cognitive impairment. |
| Q33792982 | Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles |
| Q36175389 | Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology |
| Q48494226 | Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases |
| Q35993835 | Ocular manifestations of Alzheimer's disease in animal models. |
| Q48447237 | Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. |
| Q53268119 | Personality change precedes clinical diagnosis of dementia of the Alzheimer type. |
| Q35931230 | Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer's disease |
| Q25257388 | Population-based neuropathological studies of dementia: design, methods and areas of investigation--a systematic review |
| Q48378397 | Predicting lewy body pathology in a community-based sample with clinical diagnosis of Alzheimer's disease |
| Q35837187 | Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. |
| Q36439004 | Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary. |
| Q77227270 | Progression of neurofibrillary changes and PHF-tau in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology |
| Q58127888 | Progressive language impairments: Definitions, diagnoses, and prognoses |
| Q44003364 | Progressive reduction of synaptophysin message in single neurons in Alzheimer disease |
| Q43540892 | Protein oxidation in the brain in Alzheimer's disease |
| Q31101732 | Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. |
| Q33666765 | Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease |
| Q48115020 | Redox-reactive autoantibodies in Alzheimer's patients' cerebrospinal fluids: preliminary studies |
| Q33803397 | Reduced clinical and postmortem measures of cardiac pathology in subjects with advanced Alzheimer's Disease |
| Q49145268 | Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide |
| Q43786476 | Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain |
| Q24633831 | Relationships between expression of apolipoprotein E and beta-amyloid precursor protein are altered in proximity to Alzheimer beta-amyloid plaques: potential explanations from cell culture studies |
| Q42492271 | Sequence of Abeta-protein deposition in the human medial temporal lobe. |
| Q48487066 | Severe involvement of ambient gyrus in dementia with grains |
| Q53341926 | Specific downregulation of presenilin 2 gene expression is prominent during early stages of sporadic late-onset Alzheimer's disease. |
| Q90682346 | Spectrum of tau pathologies in Huntington's disease |
| Q36123958 | Stable size distribution of amyloid plaques over the course of Alzheimer disease |
| Q48887540 | Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response |
| Q42692714 | Stereologic evidence for persistence of viable neurons in layer II of the entorhinal cortex and the CA1 field in Alzheimer disease |
| Q40887919 | Strategies for improving the postmortem neuropathological diagnosis of Alzheimer's disease |
| Q44060087 | Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias |
| Q35792254 | Subicular Dendritic Arborization in Alzheimer's Disease Correlates with Neurofibrillary Tangle Density |
| Q36607622 | Submandibular gland biopsy for the diagnosis of Parkinson disease |
| Q49056509 | Suicide and Alzheimer's pathology in the elderly: a case-control study |
| Q38891507 | Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies |
| Q39817807 | Synaptic changes in frontotemporal lobar degeneration: correlation with MAPT haplotype and APOE genotype. |
| Q34147753 | TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis. |
| Q34232167 | TDP-43 is a key player in the clinical features associated with Alzheimer's disease |
| Q39331146 | TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia |
| Q33745894 | TOMM40 in Cerebral Amyloid Angiopathy Related Intracerebral Hemorrhage: Comparative Genetic Analysis with Alzheimer's Disease |
| Q34550595 | Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). |
| Q39829758 | Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. |
| Q37073413 | The APOE ɛ4/ɛ4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients |
| Q34138207 | The Mini-Mental State exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease |
| Q34652071 | The response of cerebral cortex to haemorrhagic damage: experimental evidence from a penetrating injury model. |
| Q35632339 | The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study. |
| Q34214255 | Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid |
| Q34157421 | Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer’s disease model |
| Q40302712 | Tooth Loss and Risk of Dementia in the Community: the Hisayama Study |
| Q46067887 | Trajectories of physical function prior to death and brain neuropathology in a community-based cohort: the act study. |
| Q48661743 | Two types of sporadic cerebral amyloid angiopathy. |
| Q37205729 | Update on recent molecular and genetic advances in frontotemporal lobar degeneration |
| Q34475412 | Update on the neuropathological diagnosis of frontotemporal dementias |
| Q48949710 | Updated TDP-43 in Alzheimer's disease staging scheme |
| Q53981952 | Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease. |
| Q34114062 | Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe |
| Q34257131 | Where Vascular Meets Neurodegenerative Disease |
| Q30975987 | Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease |
| Q36626101 | X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease |
| Q22253223 | beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology |
Search more.